Samsung Bioepis and Hanmi Pharmaceutical Sign Joint Sales Agreement for Osteoporosis Treatment

Establishing a Domestic Partnership
for Prolia Biosimilar Sales

Kim Kyung-ah, President of Samsung Bioepis (left), and Park Jae-hyun, President of Hanmi Pharmaceutical (right), are taking a commemorative photo after signing a joint sales agreement. Photo by Samsung Bioepis

Samsung Bioepis and Hanmi Pharmaceutical have joined forces to sell osteoporosis treatments domestically.

Samsung Bioepis announced on the 19th that it held a joint sales agreement signing ceremony for the domestic launch of the Prolia biosimilar (active ingredient denosumab) at Hanmi Pharmaceutical's headquarters Park Hall in Songpa-gu, Seoul, the previous day.

The drug agreed upon by the two companies is a biosimilar of Prolia. Samsung Bioepis, as the developer of the Prolia biosimilar, will be responsible for the production and supply of the product, while both companies will jointly handle domestic marketing and sales activities.

Prolia is an osteoporosis treatment developed by Amgen, with global sales reaching approximately 6.5 trillion KRW as of last year. According to the market research firm IQVIA, the domestic market sales volume reached about 174.9 billion KRW last year.

Samsung Bioepis and Hanmi Pharmaceutical plan to build a close cooperative relationship to provide patients with opportunities to receive biosimilar prescriptions at more reasonable prices.

Meanwhile, Samsung Bioepis is currently undergoing the approval process for the Prolia biosimilar in Korea and obtained approval in the United States and Europe last February.

Kim Kyung-ah, President of Samsung Bioepis, stated, "Through this contract, we will closely cooperate to enable domestic patients to experience more benefits from biosimilar prescriptions based on our development capabilities and Hanmi Pharmaceutical's expertise in sales and marketing."

Park Jae-hyun, President of Hanmi Pharmaceutical, said, "Hanmi Pharmaceutical is a well-prepared partner with an established position in the musculoskeletal treatment market and has secured differentiated evidence-based marketing capabilities. Through this partnership, both companies will create innovative results for mutual growth and continue close cooperation."